| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H21N3O2 |
| Molecular Weight | 359.421 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CCN2CCC3=C(C2)C4=C(O3)C=CC=C4)C(=O)N5C=CC=CC5=N1
InChI
InChIKey=ZYXHQIPQIKTEDI-UHFFFAOYSA-N
InChI=1S/C22H21N3O2/c1-15-16(22(26)25-11-5-4-8-21(25)23-15)9-12-24-13-10-20-18(14-24)17-6-2-3-7-19(17)27-20/h2-8,11H,9-10,12-14H2,1H3
Lusaperidone (R107474) is a potent and relatively selective alpha(2)-adrenoceptor antagonist. It was under clinical evaluation for the treatment of depression, characterized by anergia and lack of drive. However, further clinical development has been stopped. Radiolabeled lusaperidone may be used as a potential radioligand for studying alpha(2)-adrenoceptors using PET.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.13 nM [Ki] | |||
| 0.15 nM [Ki] | |||
| 1.0 nM [Ki] |
PubMed
ACTIVE MOIETY
